EHA 2021 | Surrogate markers in patients with R/R myeloma receiving belantamab mafodotin
Evangelos Terpos, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, shares the findings of a post hoc analysis of the DREAMM-2 trial (NCT03525678), investigating the association between corneal exam findings, best corrected visual acuity (BCVA) changes and patient-reported ocular symptoms in patients with relapsed/refractory multiple myeloma (R/R) receiving belantamab mafodotin. Belantamab mafodotin is a B-cell maturation antigen (BCMA)-targeting antibody-drug conjugate which is approved as monotherapy in the US and the EU for the treatment of adult patients with R/R myeloma. The aim of the analysis was to determine whether BCVA changes and symptoms can guide dosing, rather than corneal exams. Prof. Terpos reports that BCVA changes and patient-reported outcomes can be used as surrogate markers to inform hematologists whether an ophthalmologist should be consulted. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Evangelos Terpos, MD, PhD, has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Genesis Pharmaceuticals, Janssen-Cilag, Novartis, Sanofi and Takeda; has participated in a consulting or advisory role for Amgen, Celgene, Genesis Pharmaceuticals, Janssen-Cilag, Sanofi and Takeda; has received research funding from Amgen, Genesis Pharmaceuticals, Janssen-Cilag, Sanofi and Takeda, and has received travel, accommodation or expenses from Amgen, Genesis Pharmaceuticals, Janssen-Cilag and Takeda.
